Ersodetug

PreclinicalSmall molecule

RRezolute

Ersodetug is one of 24 small molecule programs targeting Hypoglycemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoglycemiaActive, not recruiting

HypoglycemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

26 competitors in Hypoglycemia

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

1 2

NOVOLIN R

Novo Nordisk

Approved

1 3

Avelox

Narcan

2 5

Symlin

AstraZeneca

Approved

1 6

Proglycem

Teva

Approved

1 7

Januvia

ZZydus Therapeutics Inc.

Approved

1 8

Luxiq

SSchering-Plough

Approved

1 9

Reglan

IIstituto Clinico Humanitas

Phase 2

1 10

Avexitide

AAmylyx Pharmaceuticals Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Hyperinsulinism

NCT06881992

Clinical

Trials by Indication[1]

Hypoglycemia1 trial

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Available·RRezolute··NCT07262970

Hyperinsulinism1 trial

A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients With Inadequately Controlled Hypoglycemia Due to Tumor Hyperinsulinism (Tumor HI)

Recruiting·RRezolute·Phase 3·NCT06881992·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ersodetug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ersodetug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ersodetug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rezolute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRezolute

Ersodetug

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hypoglycemia1 trial

Hyperinsulinism1 trial

References

Drug Info

Quick Facts

Related News